177 related articles for article (PubMed ID: 19364360)
1. How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis?
Sorensen PS
Eur J Neurol; 2009 Mar; 16(3):287-8. PubMed ID: 19364360
[No Abstract] [Full Text] [Related]
2. Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis.
Putzki N; Kollia K; Woods S; Igwe E; Diener HC; Limmroth V
Eur J Neurol; 2009 Mar; 16(3):424-6. PubMed ID: 19187261
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study.
Oturai AB; Koch-Henriksen N; Petersen T; Jensen PE; Sellebjerg F; Sorensen PS
Eur J Neurol; 2009 Mar; 16(3):420-3. PubMed ID: 19364368
[TBL] [Abstract][Full Text] [Related]
4. [Choice of early and escalation treatment options for multiple sclerosis].
Linker RA; Kieseier BC
Nervenarzt; 2008 Oct; 79(10):1123-4,1126-8,1130-2 passim. PubMed ID: 18806985
[TBL] [Abstract][Full Text] [Related]
5. [Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)].
; Rieckmann P
Nervenarzt; 2006 Dec; 77(12):1506-18. PubMed ID: 17136556
[TBL] [Abstract][Full Text] [Related]
6. [Recent advances in the pathogenesis and immunotherapy of multiple sclerosis].
Gold R; Rieckmann P
Nervenarzt; 2007 Sep; 78 Suppl 1():15-24; quiz 25. PubMed ID: 17668159
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
[TBL] [Abstract][Full Text] [Related]
8. Natalizumab for relapsing multiple sclerosis.
Tenser RB
N Engl J Med; 2006 Jun; 354(22):2387-9; author reply 2387-9. PubMed ID: 16738278
[No Abstract] [Full Text] [Related]
9. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
[TBL] [Abstract][Full Text] [Related]
10. Natalizumab (Tysabri) returns.
Med Lett Drugs Ther; 2006 Sep; 48(1243):76. PubMed ID: 16977289
[No Abstract] [Full Text] [Related]
11. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
Sørensen PS
J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacological treatment of multiple sclerosis].
Myhr KM
Tidsskr Nor Laegeforen; 2010 Mar; 130(5):490-2. PubMed ID: 20224616
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
Hersh CM; Cohen JA
Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071
[TBL] [Abstract][Full Text] [Related]
15. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
Rudick RA; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Radue EW; Lublin FD; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA; Sandrock AW;
N Engl J Med; 2006 Mar; 354(9):911-23. PubMed ID: 16510745
[TBL] [Abstract][Full Text] [Related]
16. Selective treatment of multiple sclerosis.
Ropper AH
N Engl J Med; 2006 Mar; 354(9):965-7. PubMed ID: 16510751
[No Abstract] [Full Text] [Related]
17. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
[TBL] [Abstract][Full Text] [Related]
18. Assessing disability progression with the Multiple Sclerosis Functional Composite.
Rudick RA; Polman CH; Cohen JA; Walton MK; Miller AE; Confavreux C; Lublin FD; Hutchinson M; O'Connor PW; Schwid SR; Balcer LJ; Lynn F; Panzara MA; Sandrock AW
Mult Scler; 2009 Aug; 15(8):984-97. PubMed ID: 19667023
[TBL] [Abstract][Full Text] [Related]
19. [Update on current care guidelines: multiple sclerosis].
Duodecim; 2013; 129(5):548-9. PubMed ID: 23520898
[TBL] [Abstract][Full Text] [Related]
20. Natalizumab therapy for multiple sclerosis.
Chataway J; Miller DH
Neurotherapeutics; 2013 Jan; 10(1):19-28. PubMed ID: 23307290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
